Who this is for: GPs and medical officers diagnosing and titrating hypertension in adults in the OPD, reconciling ACC/AHA, ESC and NICE guidance into one workable pathway.

Epidemiology in Pakistan

Roughly one in three Pakistani adults is hypertensive, and control rates among those treated are dismal, with well under a fifth at target in national surveys. High salt intake, obesity, diabetes and low awareness drive the burden, and hypertension is the leading attributable risk factor for stroke, which strikes Pakistanis nearly a decade earlier than Western cohorts. The OPD blood pressure cuff is the highest-yield screening tool in the building.

Diagnosis: measure properly, confirm out of office

Technique first: seated 5 minutes, back supported, correct cuff size, arm at heart level, no talking, average of 2 to 3 readings, both arms at first assessment (use the higher arm subsequently).

Classification per ACC/AHA 2017: normal below 120/80; elevated 120 to 129 with diastolic below 80; stage 1: 130 to 139 or 80 to 89; stage 2: 140/90 or more. ESC 2024 introduces an intermediate elevated BP category of 120 to 139 systolic or 70 to 89 diastolic, with hypertension still defined at 140/90. NICE NG136 diagnoses at clinic 140/90 or more confirmed by ambulatory or home monitoring at 135/85 or more.

Out-of-office confirmation matters: white-coat effect is common. Where ABPM is unavailable (most of Pakistan), home BP monitoring with a validated automated device, twice daily for 7 days, discarding day one and averaging the rest, is the NICE-endorsed alternative and is affordable in most cities.

Baseline workup, cheapest first: urine dipstick and ACR if possible, creatinine with eGFR, electrolytes, fasting glucose or HbA1c, lipids, ECG for LVH. Examine for radio-femoral delay and renal bruits. Suspect secondary hypertension in patients under 30, resistant hypertension on three drugs, hypokalaemia, or abrupt onset.

Treatment thresholds and targets, age-stratified

  • Start drugs at stage 2 (140/90 or more) for everyone alongside lifestyle change.
  • Start at stage 1 (130 to 139/80 to 89) when 10-year ASCVD risk is 10 percent or more, or with diabetes, CKD or established CVD (ACC/AHA).
  • Target below 130/80 for most treated adults per ACC/AHA; ESC 2024 recommends aiming for systolic 120 to 129 if tolerated.
  • Over-80s per NICE: treatment threshold clinic 150/90, target below 150/90; per ACC/AHA a target below 130 systolic is reasonable in fit, community-dwelling elderly. In frail elderly, check standing BP, titrate slowly and accept looser targets; orthostatic falls cause more harm than a few mm Hg.

Lifestyle for all: salt below 5 g per day (name the salt in achar, papar, chaat masala and processed snacks explicitly), weight loss, 150 minutes weekly activity, DASH-pattern diet, smoking and smokeless tobacco (naswar, gutka) cessation, limiting stress and improving sleep.

Drug selection

All first-line classes are available as inexpensive DRAP-registered generics:

  • ACE inhibitor or ARB (lisinopril, ramipril; losartan, valsartan): first choice under 55 and in diabetes, CKD with albuminuria, or heart failure (NICE logic). Check creatinine and potassium 2 to 4 weeks after starting; a creatinine rise up to 30 percent is acceptable. Never combine ACEi with ARB. Absolutely contraindicated in pregnancy; ask every woman of childbearing age.
  • Calcium channel blocker (amlodipine 5 to 10 mg): NICE first choice for age 55 and over; excellent in the elderly and cheap.
  • Thiazide-like diuretic (indapamide 1.5 mg SR, or hydrochlorothiazide where that is what the pharmacy stocks): third pillar; watch sodium and potassium in the elderly.
  • Most patients need two drugs; start stage 2 patients on dual low-dose therapy from day one (ESC and ACC/AHA both endorse initial combination), ideally as a single-pill combination to protect adherence.
  • Resistant hypertension (uncontrolled on ACEi/ARB plus CCB plus diuretic at optimal doses): confirm adherence and home readings, then add spironolactone 25 mg if potassium is below 4.5 and eGFR above 45, and look for secondary causes.
  • Beta-blockers are not first line for uncomplicated hypertension; reserve them for angina, post-MI, heart failure or rate control.

Red flags: refer or admit same day

Clinic BP 180/120 or more with chest pain, breathlessness, neurological deficit, visual symptoms, or AKI is a hypertensive emergency: refer immediately, do not drop the pressure precipitously with sublingual nifedipine (this practice persists in Pakistan and causes strokes). BP 180/120 without organ damage: start or intensify oral therapy and review within days. Also refer: suspected secondary hypertension, pregnancy with BP 140/90 or more (pre-eclampsia pathway), and eGFR below 30.

Follow-up schedule

Review monthly while titrating, checking home BP logs; electrolytes and creatinine after each ACEi/ARB or diuretic change; once controlled, review every 3 to 6 months with annual bloods, ECG and ACR. Adherence is the battleground: single-pill combinations, morning dosing and asking non-judgementally about missed doses beat any new molecule. MyPatient AI-prepared intakes pull home BP readings and current drug lists into the note before the visit, so titration decisions start from real data. Give patients the patient guide to share.

Key points

  • Confirm diagnosis with home or ambulatory readings (135/85 threshold) before lifelong therapy.
  • Stage 1 is 130 to 139/80 to 89 (ACC/AHA); treat it with drugs when risk or comorbidity is present.
  • Target below 130/80 for most; NICE allows below 150/90 in over-80s; go gently in the frail.
  • Under 55: ACEi/ARB; 55 and over: amlodipine; most need two drugs, ideally one pill.
  • Ban sublingual nifedipine for BP spikes; screen every 180/120 for organ damage.
  • Check creatinine and potassium after every ACEi, ARB or diuretic change.

References

  • 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. American College of Cardiology and American Heart Association, 2017.
  • 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. European Society of Cardiology, 2024.
  • Hypertension in Adults: Diagnosis and Management, NG136. National Institute for Health and Care Excellence, 2019 (updated 2023).
  • HEARTS Technical Package for Cardiovascular Disease Management in Primary Health Care. World Health Organization, 2020.
  • 2020 International Society of Hypertension Global Hypertension Practice Guidelines. ISH, 2020.

Clinical judgement and local protocols take precedence.